Kwality Pharmaceuticals Ltd
NSE: BSE: 539997
₹1058
(-0.69)%
Mon, 02 Feb 2026, 02:30 am
Market Cap11.05B
PE Ratio22.38
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KAnalysis
dividend
- Unable to calculate sustainability of dividends as Kwality Pharmaceuticals has not reported any payouts.
- Unable to evaluate Kwality Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Kwality Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Kwality Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Kwality Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Kwality Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (63.2%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 3.9x debt.
- Kwality Pharmaceuticals's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 6x coverage).
- The level of debt compared to net worth has increased over the past 5 years (37.4% vs 53% today).
- Kwality Pharmaceuticals's level of debt (53%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Kwality Pharmaceuticals board of directors is about average.
- Ramesh's remuneration is lower than average for companies of similar size in India.
- Ramesh's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Kwality Pharmaceuticals management team is about average.
misc
- Kwality Pharmaceuticals is not covered by any analysts.
- Kwality Pharmaceuticals's last earnings update was 215 days ago.
- Kwality Pharmaceuticals has significant price volatility in the past 3 months.
past
- Kwality Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (55.5% vs 39.2%)
- Kwality Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
- Kwality Pharmaceuticals used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Kwality Pharmaceuticals has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Kwality Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Kwality Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (55.5% vs 22.7%).
value
- Kwality Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Kwality Pharmaceuticals is good value based on assets compared to the IN Pharmaceuticals industry average.
- Kwality Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Kwality Pharmaceuticals is good value based on earnings compared to the India market.
- Kwality Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- BSE:539997 is down -3.3% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:539997 is down -3.3% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800